miR-143、miR-145在胰腺癌患者血清中的表达情况及与患者临床参数的相关性分析

Expression of miR-143 and miR-145 in serum of patients with pancreatic cancer and their correlation with clinical parameters

目的:探讨miR-143、miR-145在胰腺癌患者血清中的表达情况及与患者临床参数的相关性。方法:选取我院收治的98例胰腺癌患者作为胰腺癌组,另选50例健康对照组,采用实时荧光定量PCR方法检测两组血清miR-143、miR-145表达情况,收集胰腺癌组患者临床资料,并根据临床资料进行分组,Logistics回归分析胰腺癌组临床参数与miR-143、miR-145表达的相关性。结果:胰腺癌组血清miR-143和miR-145表达存在显著正相关关系(P<0. 05);与健康对照组比较,胰腺癌组患者血清miR-143、miR-145表达显著降低(P<0. 05);胰腺癌患者血清中miR-143和miR-145的表达和患者肿瘤TMN分期、肿瘤直径、性别、肿瘤部位以及年龄无关系(P>0. 05),miR-143为胰腺癌发病的保护因素(P=0. 032,OR=0. 257)。与健康对照组比,胰腺癌组血清miR-143和miR-145表达水平显著降低(P<0. 05);与治疗前比,治疗后胰腺癌组血清miR-143和miR-145表达水平显著提高(P<0. 05),但与健康对照组比仍然较低(P<0. 05)。结论:胰腺癌患者血清miR-143和miR-145表达低于健康者,且两者呈正相关关系,miR-143为胰腺癌发病的保护因素,胰腺癌治疗后miR-143和miR-145表达显著增高;胰腺癌患者血清miR-143、miR-145表达水平与胰腺癌患者临床相关参数指标无显著相关性。

Objective： To investigate the expression of miR-143 and miR-145 in the serum of patients with pancreatic cancer and its correlation with clinical parameters. Methods： 98 cases of pancreatic cancer patients admitted to our hospital as a pancreatic cancer group,another 50 healthy control group,real-time fluorescent quantitative PCR method was used to detect the expression of miR-143 and miR-145 in the two groups,clinical data of patients with pancreatic cancer were collected and grouped according to the clinical data. The correlation between the clinical parameters and the expression of miR-143 and miR-145 in pancreatic cancer was analyzed by Logistics. Results： There was a significant positive correlation between the expression of miR-143 and miR-145 in pancreatic cancer（P〈0. 05）. Compared with healthy control group,the expression of miR-143 and miR-145 in pancreatic cancer patients was significantly lower（P〈0. 05）. The expression of miR-143 and miR-145 in the serum of patients with pancreatic cancer had no relationship with TMN stage,average tumor diameter,sex,tumor location and age（P〈0. 05）. MiR-143 was a protective factor in the pathogenesis of pancreatic cancer（P = 0. 032,OR = 0. 257）. Compared with the healthy control group,the serum miR-143 and miR-145 in pancreatic cancer group were significantly decreased（P〈0. 05）. Compared with before treatment,the serum miR-143 and miR-145 in pancreatic cancer group were significantly higher after treatment（P〈0. 05）. The serum miR-143 and miR-145 in pancreatic cancer group after treetment were still lower than the healthy control group（P〈0. 05）. Conclusion： Serum levels of miR-143 and miR-145 in pancreatic cancer patients are lower than those in healthy persons. There was a positive correlation between miR-143 and miR-145. MiR-143 is a protective factor in the pathogenesis of pancreatic cancer. After treatment,the serum miR-143 and miR-145 are higher than before treatment. The expression of miR-143 and miR-145 in pancreatic cancer patients has no significant correlation with clinical parameters of pancreatic cancer patients.